African-American patients with advanced prostate cancer survived slightly longer than white patients, according to a multi-institutional study led by Dana-Farber Cancer Institute researchers. The findings, which were reported at the 38th annual
African-American patients with advanced prostate cancer survived slightlylonger than white patients, according to a multi-institutional study led byDana-Farber Cancer Institute researchers. The findings, which were reported atthe 38th annual meeting of the American Society of Clinical Oncology, contradictthe conventional notion that African-Americans with the disease die sooner.
The data were drawn from a pooled analysis of four randomized clinical trialsin men with advanced prostate cancer that no longer responded to hormonetreatments. On average, African-Americans in the trials survived for median of15 months, whereas whites survived for a median of 14 months.
"This is evidence that African-Americans do just as well as whites whenthey’re treated within the context of a clinical trial," said Timothy D.Gilligan, md, a genitourinary oncologist at Dana-Farber. "This shoulddiscourage a pessimistic approach to prostate cancer in African-Americans inthis setting."
Treatment Discrepancies
The finding, said Dr. Gilligan, challenges epidemiologic evidence, which hassuggested that prostate cancer is more aggressive in African-Americans than inwhite men. Studies have shown that African-Americans typically are diagnosedwith more advanced disease and have a higher mortality rate than whites. Dr.Gilligan said differences in treatment could explain the discrepancy.
The researchers from several institutions including Dana-Farber, DukeUniversity, the University of Maryland, the University of California at SanFrancisco, and the University of Chicago pooled the outcomes of four trials ofseveral different treatments for hormone-refractory prostate cancer. A total of844 white men and 144 African-American men were enrolled in the studies. Theiraverage age was 71 years, and 90% had metastases to other organs.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.